Tag Archives: Johnson & Johnson

Paused: Eli Lilly monoclonal antibody study and J&J COVID-19 vaccine trials

By on .

By Daniel R. Lucey M.D., MPH, FIDSA In the past 24 hours both the Johnson & Johnson Phase 3 single-dose vaccine study, and the Eli Lilly monoclonal antibody study (studies?) have been paused, and their Data-Safety Monitoring Board (DSMB) convened to evaluate safety concern(s). Johnson and Johnson (J&J)  issued a statement saying: “We have temporarily […]

In face of ongoing Ebola response challenges, WHO adapts vaccine strategy to streamline process, expand access, extend supply

By on .

“Pop-up” vaccination sites, widened eligibility for inoculations, reduced doses, and the addition of a new investigational vaccine candidate are among the strategies a panel of World Health Organization experts has recommended to reverse discouraging trends, including increased cases and continuing security threats confronting responses to the ongoing Ebola outbreak in the Democratic Republic of Congo. […]

Groups seek recognition of global health response “secret weapon”

By on .

When people talk about the how life-saving medicine finally made it to poor countries, how tuberculosis patients far from clinics finished grueling treatment courses, and how 50 million or so newborns made it past infancy over the last 20 years because their mothers, and they, got the treatment they needed, the talk is often of […]